Core Insights - The Guangxi Fangchenggang International Medical Open Experimental Zone is attracting pharmaceutical companies, facilitating cross-border medical cooperation and market expansion for enterprises [1][2][4] Group 1: Company Developments - Guangxi Fangchenggang City Kunze Pharmaceutical Co., Ltd. plans to complete the construction of a traditional Chinese medicine extraction and processing line by December 2024, with a target of registering 150 product varieties this year and achieving a production value of 25 million yuan [1] - Guangxi Ganhua Zhenmei Biotechnology Co., Ltd. has developed a low-temperature preparation technology for active peptide crystals, addressing the low utilization rate of domestic peptide products, and aims to enter ASEAN markets within three years [2] Group 2: Industry Growth and Projections - The experimental zone is projected to attract over 6 billion yuan in investment by 2025, with a total output value of 5 billion yuan from medical devices and traditional pharmaceutical industries [2] - The zone serves as a gateway for Chinese enterprises to access ASEAN markets, facilitating import and export trade, including plans to import medicinal materials from ASEAN countries [2] Group 3: International Collaboration - The zone has established international cooperation bridges, hosting forums to deepen collaboration with countries like Belarus and Uzbekistan, and is working on setting up overseas centers for traditional Chinese medicine in Russia and Vietnam [2][4] - The "1369 Life Express" green channel for cross-border medical assistance has facilitated medical services for over 60,000 Vietnamese patients in the past six years, enhancing the reputation of pharmaceutical products [3]

Core Viewpoint - The announcement indicates that the wholly-owned subsidiary of the company, Baoding Tianhao Pharmaceutical Co., Ltd., has received approval from the Hebei Provincial Drug Administration for changes in its production license, which will positively impact the company's future operations [1] Group 1 - The production license changes include modifications to the production scope for oral suspensions and tablets, as well as shared use of traditional Chinese medicine extraction and granules with Shandong Buchang Shenzhou Pharmaceutical Co., Ltd. [1] - The validity of the new production license is until July 7, 2030, which provides a long-term framework for the company's production capabilities [1] - These changes are expected to optimize the company's production structure and maintain stable production capacity to meet market demand [1]